Diane Seimetz

1.1k total citations
21 papers, 839 citations indexed

About

Diane Seimetz is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Diane Seimetz has authored 21 papers receiving a total of 839 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Diane Seimetz's work include Immunotherapy and Immune Responses (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (5 papers). Diane Seimetz is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (5 papers). Diane Seimetz collaborates with scholars based in Germany, Austria and Italy. Diane Seimetz's co-authors include Horst Lindhofer, R. Linke, Carsten Bokemeyer, Jan Richter, Michael Hennig, Marion Ott, Frederik Marmé, Gerhard Moldenhauer, Judith Atz and Thomas Biedermann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Diane Seimetz

20 papers receiving 794 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diane Seimetz Germany 12 435 355 304 293 79 21 839
Jianying Gu China 18 246 0.6× 184 0.5× 427 1.4× 116 0.4× 90 1.1× 47 923
Pamela M.J. McLaughlin Netherlands 14 348 0.8× 97 0.3× 456 1.5× 212 0.7× 85 1.1× 22 893
Samir Tawadros Germany 16 225 0.5× 142 0.4× 254 0.8× 352 1.2× 91 1.2× 34 863
Sarah E. Nicholas United States 15 224 0.5× 276 0.8× 172 0.6× 159 0.5× 47 0.6× 38 807
Gijs Verheijden Netherlands 11 367 0.8× 385 1.1× 313 1.0× 262 0.9× 19 0.2× 21 847
F I Preffer United States 11 158 0.4× 109 0.3× 159 0.5× 307 1.0× 90 1.1× 20 730
L Deneux France 11 344 0.8× 130 0.4× 378 1.2× 316 1.1× 58 0.7× 17 838
Jason B. Muhitch United States 14 628 1.4× 43 0.1× 281 0.9× 649 2.2× 70 0.9× 33 1.2k
Laurence Maggiorella France 11 291 0.7× 81 0.2× 340 1.1× 73 0.2× 46 0.6× 17 793
Heidi Braumüller Germany 16 543 1.2× 93 0.3× 266 0.9× 908 3.1× 93 1.2× 27 1.3k

Countries citing papers authored by Diane Seimetz

Since Specialization
Citations

This map shows the geographic impact of Diane Seimetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane Seimetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane Seimetz more than expected).

Fields of papers citing papers by Diane Seimetz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane Seimetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane Seimetz. The network helps show where Diane Seimetz may publish in the future.

Co-authorship network of co-authors of Diane Seimetz

This figure shows the co-authorship network connecting the top 25 collaborators of Diane Seimetz. A scholar is included among the top collaborators of Diane Seimetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane Seimetz. Diane Seimetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Seimetz, Diane, et al.. (2020). Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. Biomarker Insights. 15. 2138514105–2138514105. 62 indexed citations
3.
Seimetz, Diane, et al.. (2019). Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?. PubMed. 11. 3084395645–3084395645. 65 indexed citations
4.
Seimetz, Diane, et al.. (2019). From fiction to science: clinical potentials and regulatory considerations of gene editing. SHILAP Revista de lepidopterología. 8(1). 27–27. 26 indexed citations
5.
Seimetz, Diane, et al.. (2018). Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation. Therapeutic Innovation & Regulatory Science. 53(3). 364–373. 22 indexed citations
6.
Piaggesi, Alberto, Severin Läuchli, Franco Bassetto, et al.. (2018). Advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies. Journal of Wound Care. 27(Sup6a). S1–S137. 44 indexed citations
7.
Heiss, M. M., Michael A. Ströhlein, Carsten Bokemeyer, et al.. (2014). The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study. Clinical Cancer Research. 20(12). 3348–3357. 18 indexed citations
8.
Atanackovic, Djordje, Henrike Reinhard, Sabrina Meyer, et al.. (2013). The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Human Vaccines & Immunotherapeutics. 9(12). 2533–2542. 22 indexed citations
9.
Lindemann, Carsten, et al.. (2012). Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo. Clinical & Translational Oncology. 14(5). 376–381. 10 indexed citations
10.
Seimetz, Diane. (2011). Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®). SHILAP Revista de lepidopterología. 3 indexed citations
11.
Lindemann, Carsten, et al.. (2011). Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clinical & Translational Oncology. 13(12). 889–898. 11 indexed citations
12.
Ott, Marion, Frederik Marmé, Gerhard Moldenhauer, et al.. (2011). Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites. International Journal of Cancer. 130(9). 2195–2203. 63 indexed citations
13.
Seimetz, Diane. (2011). Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®). Journal of Cancer. 2. 309–316. 63 indexed citations
14.
Ruf, Peter, et al.. (2011). Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites.. Journal of Clinical Oncology. 29(15_suppl). 2575–2575. 3 indexed citations
15.
Reinhard, Henrike, Saskia Meyer, Katrin Bartels, et al.. (2011). The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer.. Journal of Clinical Oncology. 29(15_suppl). 2601–2601. 1 indexed citations
16.
Hennig, Michael, et al.. (2011). Effect of catumaxomab treatment in patients with peritoneal carcinomatosis and malignant ascites due to gastrointestinal cancers on survival.. Journal of Clinical Oncology. 29(4_suppl). 490–490. 1 indexed citations
17.
Seimetz, Diane, Horst Lindhofer, & Carsten Bokemeyer. (2010). Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy. Cancer Treatment Reviews. 36(6). 458–467. 211 indexed citations
18.
Linke, R., et al.. (2010). Catumaxomab. mAbs. 2(2). 129–136. 203 indexed citations
19.
Ott, Marion, Horst Lindhofer, Martin Hennig, et al.. (2010). The trifunctional antibody catumaxomab: Correlation between immunological response and clinical outcome—New analysis of a pivotal phase II/III study.. Journal of Clinical Oncology. 28(15_suppl). 2551–2551. 1 indexed citations
20.
Seimetz, Diane, Eva Frei, Martina Schnölzer, Tore Kempf, & Manfred Wießler. (1999). One Step Isolation of Bovine Asialoglycoprotein Receptor and Its Characterization by Sequence Analysis and MALDI Mass Spectrometry. Bioscience Reports. 19(2). 115–124. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianying Gu Breakdown of academic impact, for papers by Pamela M.J. McLaughlin Breakdown of academic impact, for papers by Samir Tawadros Breakdown of academic impact, for papers by Sarah E. Nicholas Breakdown of academic impact, for papers by Gijs Verheijden Breakdown of academic impact, for papers by F I Preffer Breakdown of academic impact, for papers by L Deneux Breakdown of academic impact, for papers by Jason B. Muhitch Breakdown of academic impact, for papers by Laurence Maggiorella Breakdown of academic impact, for papers by Heidi Braumüller
Rankless by CCL
2026